RAD 5.41% 3.5¢ radiopharm theranostics limited

Ann: Radiopharm Receives Strategic Investment for up to A$18 mill, page-8

  1. 1,500 Posts.
    lightbulb Created with Sketch. 497
    One of the assets that Lantheus has taken was LRRC15 antibody for osteosarcoma (aggressive bone cancer).

    It has both ODD and RPDD from the FDA.

    I hope we don't regret selling it cheap.
 
watchlist Created with Sketch. Add RAD (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.